Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
CagriSema 2.4 mg/2.4 mg Improves Metabolic Syndrome in Adults With Overweight or Obesity, Without Type 2 Diabetes: A Post hoc Analysis of REDEFINE 1
Authors:
Matthias Blüher1; Kasper Adelborg2; Melanie J. Davies3; Ildiko Lingvay4; Christian Bøge Lyndgaard2; Rasmus Sørrig2; John P. H. Wilding5; Ania M. Jastreboff6
Affiliations
Post hoc<\/i> Analysis of REDEFINE 1\n`)" v-cloak>
View DetailsHide Details